Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1681
    +0.0025 (+0.21%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.14%)
     

  • Bitcoin GBP

    51,170.34
    -744.87 (-1.43%)
     

  • CMC Crypto 200

    1,332.39
    -64.14 (-4.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.64
    +0.07 (+0.08%)
     

  • GOLD FUTURES

    2,349.20
    +6.70 (+0.29%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Company News for Jul 8, 2019

Zacks Equity Research

  • Shares of Oasmia Pharmaceutical AB OASM jumped 63.4% after the company reached an agreement with its largest shareholder Arwidsro regarding outstanding balances

  • Gol Linhas Aéreas Inteligentes S.A. GOL shares surged 17.2% after the company reported that its preliminary passenger traffic for June increased 12.6% year over year

  • Grifols S.A. GRFS shares gained 1,3% after the FDA approved its new drugXembify for the treatment of primary immunodeficiencies

  • Shares of Dell Technologies Inc. DELL declined 1% following news that the company willshift substantial production capacity out of China


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Gol Linhas Aereas Inteligentes S.A. (GOL) : Free Stock Analysis Report
 
Dell Technologies Inc. (DELL) : Free Stock Analysis Report
 
Grifols, S.A. (GRFS) : Free Stock Analysis Report
 
Oasmia Pharmaceutical AB (OASM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research